Artal Group’s Stemline Therapeutics, Inc. STML Stock Holding History

Artal Group’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-360,000	Closed	-$3.83M	–	122
2019 Q4	$3.83M	Hold	360,000	–	–	0.15%	81
2019 Q3	$3.75M	Hold	360,000	–	–	0.15%	81
2019 Q2	$5.51M	Sell	360,000 -40,000	-10%	-$579K	0.22%	74
2019 Q1	$5.14M	Hold	400,000	–	–	0.21%	73
2018 Q4	$3.8M	Hold	400,000	–	–	0.14%	75
2018 Q3	$6.64M	Hold	400,000	–	–	0.17%	65
2018 Q2	$6.42M	Hold	400,000	–	–	0.14%	61
2018 Q1	$6.12M	Buy	400,000 +200,000	+100%	+$3.12M	0.08%	62
2017 Q4	$3.12M	Sell	200,000 -50,000	-20%	-$669K	0.05%	83
2017 Q3	$2.77M	Hold	250,000	–	–	0.05%	84
2017 Q2	$2.3M	Buy	250,000 +150,000	+150%	+$1.25M	0.04%	93
2017 Q1	$855K	Buy	+100,000	New	+$911K	0.02%	90
2014 Q4	–	Sell	-170,000	Closed	-$2.12M	–	104
2014 Q3	$2.12M	Hold	170,000	–	–	0.08%	79
2014 Q2	$2.49M	Buy	170,000 +15,000	+10%	+$230K	0.1%	77
2014 Q1	$3.16M	Sell	155,000 -15,000	-9%	-$364K	0.11%	84
2013 Q4	$3.33M	Buy	+170,000	New	+$4.54M	0.12%	69

Other funds holding STML

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Artal Group's STML Position: Q1 2020 in Review

Artal Group sold out of Stemline Therapeutics, Inc. (STML) in Q1 2020, closing a stake of 360,000 shares — an estimated $3.83M sold.

Artal Group first reported a position in STML in Q4 2013 and held it in 16 quarters. The position peaked at $6.64M in Q3 2018. 94 funds tracked by Wall St. Rank hold STML as of Q1 2020.

Artal Group reported no remaining Stemline Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
Artal Group sold 360,000 Stemline Therapeutics, Inc. shares in Q1 2020, an estimated $3.83M.
Artal Group first reported a position in Stemline Therapeutics, Inc. in Q4 2013 and held it in 16 quarters.
Artal Group's Stemline Therapeutics, Inc. position peaked at $6.64M in Q3 2018.
94 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2020.

Based on Artal Group's 13F filing for Q1 2020, filed 14 May 2020.